Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Episodes
125 total · newest first
Press play on any episode and the show keeps running from there.
M&A Speed Bumps, “Normal” IPO but not approach, two updates, and FDA gives nod to menstrual bleeding, prostate cancer, and COVID19 monoclonal antibodies.Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-052…
Oncology on the move, an industry report looking at broader trends, good news in Alzheimer’s, and another niche oncology therapy approved. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-051-1https://tinyurl.…
Two FDA approvals, cellulite and tattoos, Ginkgo pulls in $2.5B, and Caris massive growth equity for oncology testing. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-50-1https://tinyurl.com/Niche-50-2https:/…
Critical intellectual property move by Biden-Harris, Pfizer goes for full approval, SPAC 1, SPAC 2, Regeneron drops big numbers, and an IPO gets punted. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-049-1ht…
Welcome to a monthly bonus episode. I sat down with Dr. Amir Kalali, the co-chair of the Decentralized Trials & Research Alliance (DTRA) – a clinical research coalition of the most influential companies in the field to talk about decent…
The FDA slaps wrists and takes names, Farxiga expands FDA approval, BioVie makes cash-light acquisition, Pfizer targets fungus, and one IPO down, another to go. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche…
Billion-dollar amendments, billion-dollar funds, GSK gets oncology nod from FDA, and two stories in clinical research. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-046-1https://tinyurl.com/Niche-046-2https…
Gilead gets FDA approval in oncology, Bio-Techne acquires Asuragen, AI for tumor targeting, and Achilles completes $175M IPO. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-044-1https://tinyurl.com/Niche-044…
Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C. Sponsorshttps://www.thescopemethod.com Story Referenceshttps://tinyurl.com/Niche-043-1https://tinyurl.com…
This is our March bonus episode. I sit down with Dr. Benjamin Schwartz an orthopedic surgeon and digital health expert. We talk digital integration, healthcare cost, and how you can get involved in the space. Sponsorshttps://www.thescopemet…
Mergers in precision oncology testing, Medtronic breakthrough valve replacement, Gyroscope raises capital for AMD, and small molecule genetic treatments get $240M IPO.Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com…
A new MS therapeutic, Fujifilm picks CDMO facility site, consolidation in medical services, and a new oncology startup. Sponsorshttps://www.thescopemethod.com Story Referenceshttps://tinyurl.com/Niche-040-1https://tinyurl.com/Niche-040-2htt…
92% reduction in COVID mortality, AVEO gets FDA approval, Takeda acquires Maverick and targets emerging markets, and AgomAb raises $74M Series B for regenerative medicine. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyur…
Amgen nabs Five Prime Therapeutics in $1.9B deal, KemPharm ligates their way out of debt with ADHD, three failed COVID19 pipelines, and Colfax follows 2019 merger with corporate split. Sponsorshttps://www.thescopemethod.comStory Referencesh…
I sit down with Dr. Mitrani, the Chief Scientific Officer for Organicell, a clinical stage biopharma company focused on regenerative medicine. Their leading product, Zofin is currently in early clinical trials for the treatment of COVID19. …
PRA acquired by Icon, Johnson & Johnson’s vaccine approved, Oncopeptides’ earns FDA approval, Roivant acquires Silicone Therapeutics, and Merck acquires Pandion.Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/n…
Eli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time. Sponsor…
Two Mercks - three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-33-Merck1https://tinyurl.com/Niche-33-…
Biogen gets punted but it’s good, lupus breakthroughs, Senseonics raises capital, and Novavax and Johnson & Johnson… and Janssen.Sponsorshttps://www.thescopemethod.comStory Referenceshttps://tinyurl.com/Niche-032-1https://tinyurl.com/Ni…
This is our January interview bonus. I sit down with John Reites, founder and CEO of Thread Research to discuss eCOA, decentralized clinical trials past, present, and future, and how you can think about a decentralized approach to your proj…
Thermo Fisher Scientific spends a billion, Boston Scientific also spends a billion and gets FDA approval, Verve pulls $94 million for CRISPR in humans, and Vera raises $80 million for Berger’s diseaseSponsorshttps://www.thescopemethod.comSt…
100 million vaccines, EvoQ’s NanoDisk, Merck gets FDA priority, and startups in wearables, startups in diagnostics. Sponsorshttps://www.thescopemethod.com Story Referenceshttps://tinyurl.com/Niche029-1https://tinyurl.com/Niche029-2https://t…
